CINECA IRIS Institutional Research Information System

TUCCI, Marcello
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.809
EU - Europa 2.517
AS - Asia 1.717
SA - Sud America 136
OC - Oceania 125
AF - Africa 61
Continente sconosciuto - Info sul continente non disponibili 8
Totale 8.373
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.606
CN - Cina 914
IT - Italia 658
JP - Giappone 235
DE - Germania 219
GB - Regno Unito 214
IE - Irlanda 212
FR - Francia 177
SE - Svezia 171
CA - Canada 160
ES - Italia 150
AU - Australia 116
IN - India 109
UA - Ucraina 108
AT - Austria 107
PL - Polonia 81
VN - Vietnam 72
KR - Corea 71
HK - Hong Kong 61
NL - Olanda 61
BE - Belgio 58
BR - Brasile 56
TW - Taiwan 45
FI - Finlandia 42
TR - Turchia 40
CH - Svizzera 38
GR - Grecia 37
MX - Messico 35
SG - Singapore 34
RU - Federazione Russa 29
DK - Danimarca 27
CL - Cile 26
CO - Colombia 26
PT - Portogallo 26
IL - Israele 22
ID - Indonesia 19
RO - Romania 18
NO - Norvegia 17
PH - Filippine 15
TH - Thailandia 15
IR - Iran 14
ZA - Sudafrica 12
KE - Kenya 11
RS - Serbia 11
AR - Argentina 10
HR - Croazia 9
HU - Ungheria 9
LB - Libano 9
NG - Nigeria 9
NZ - Nuova Zelanda 9
SK - Slovacchia (Repubblica Slovacca) 9
EC - Ecuador 8
EU - Europa 8
IQ - Iraq 8
LT - Lituania 8
PE - Perù 7
PK - Pakistan 7
GH - Ghana 6
CZ - Repubblica Ceca 5
EG - Egitto 5
MY - Malesia 5
BG - Bulgaria 4
LV - Lettonia 4
MA - Marocco 4
LY - Libia 3
MO - Macao, regione amministrativa speciale della Cina 3
NI - Nicaragua 3
SI - Slovenia 3
SY - Repubblica araba siriana 3
VE - Venezuela 3
AM - Armenia 2
BJ - Benin 2
CY - Cipro 2
EE - Estonia 2
KZ - Kazakistan 2
MT - Malta 2
NE - Niger 2
PR - Porto Rico 2
QA - Qatar 2
SA - Arabia Saudita 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
CG - Congo 1
CR - Costa Rica 1
CU - Cuba 1
ET - Etiopia 1
GE - Georgia 1
JM - Giamaica 1
JO - Giordania 1
LU - Lussemburgo 1
MN - Mongolia 1
PS - Palestinian Territory 1
SN - Senegal 1
TG - Togo 1
UZ - Uzbekistan 1
ZM - Zambia 1
Totale 8.373
Salva come PNG Salva come JPEG
Città #
Chandler 356
Beijing 244
Redwood City 222
Fairfield 216
Dublin 204
Ashburn 166
Houston 155
Wilmington 139
Seattle 123
Woodbridge 119
Nyköping 103
Torino 98
Shanghai 97
Vienna 88
Pisa 85
Cambridge 81
Ann Arbor 76
Tokyo 74
Guangzhou 71
Jacksonville 60
Villeurbanne 49
Medford 47
Princeton 47
Warsaw 47
Dong Ket 46
Chengdu 44
Nanjing 41
London 40
Turin 36
Dearborn 35
Taipei 31
Fremont 29
Milan 28
New York 28
Jinan 27
Duncan 26
Toronto 26
Boston 25
Hangzhou 24
Wuhan 24
Paris 23
Ottawa 22
San Diego 22
Binbrook 20
Shenyang 20
Changsha 18
Kalundborg 18
Madrid 18
Santiago 18
Zhengzhou 18
Seoul 17
Athens 16
Montréal 16
Peoria 16
Québec 16
Rome 15
Bengaluru 14
Chicago 14
Helsinki 14
Los Angeles 14
Raritan 14
Sydney 14
Brisbane 13
Central District 13
Istanbul 13
Philadelphia 13
Berlin 12
Chennai 12
Hong Kong 12
Melbourne 12
Brussels 11
Erlangen 11
Singapore 11
Chongqing 10
Evanston 10
Hefei 10
Kunming 10
San Francisco 10
Sewell 10
Vancouver 10
Atlanta 9
Barcelona 9
Belgrade 9
Düsseldorf 9
Nanchang 9
Piemonte 9
Xian 9
Boardman 8
Buffalo 8
Central 8
Derby 8
Harbin 8
Naples 8
New Delhi 8
Phoenix 8
Salt Lake City 8
Southampton 8
Tianjin 8
Valencia 8
Arlington 7
Totale 4.223
Salva come PNG Salva come JPEG
Nome #
Papillary renal cell carcinoma: A review of the current therapeutic landscape 1.243
Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: A systematic review and meta-analysis 1.150
Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer 1.123
Hormonal treatment and quality of life of prostate cancer patients: new evidences 640
Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain 586
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer 480
Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer 327
The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome 263
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era 188
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer 159
Pros-IT CNR: an Italian prostate cancer monitoring project 146
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment 144
Immediate or delayed nephrectomy in patients with metastatic renal cancer who are receiving targeted agents: Is the analysis at risk for guarantee- time bias? 131
C28Sequencing cabazitaxel and new generation hormonal treatments in metastatic castration resistant prostate cancer patients after first line docetaxel: a retrospective analysis 126
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study 110
Enzalutamide-resistant castration-resistant prostate cancer: Challenges and solutions 104
An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer 100
Immunotherapy for patients with advanced urothelial cancer: Current evidence and future perspectives 99
Androgen deprivation modulates gene expression profile along prostate cancer progression 93
223Ra Dichloride Bone-Targeted Therapy in a Case of Metastatic Salivary Duct Carcinoma 90
FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: A case report 87
PROGNOSTIC ROLE OF SERUM TESTOSTERONE LEVELS IN PROSTATE CANCER PATIENTS DURING ANDROGEN-DEPRIVATION THERAPY 79
LATITUDE and other coordinates in quality of life of prostate cancer patients 79
Circadian variation of breakthrough pain in cancer patients. 70
Zoledronic Acid Dosing Interval for Metastatic Cancer 66
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents 62
Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. 57
68 Ga-PSMA Uptake in Fibrous Dysplasia 56
Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel 53
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside 51
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives 47
Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review 44
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 43
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2 43
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis 39
Prognostic factors in metastatic castration resistant prostate cancer patients treated with Radium-223: a retrospective study 37
Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report 36
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives 32
New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? 32
Prognostic role of early PSa drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide 30
Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine? 29
Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications 29
Evaluation of cognitive function in trials testing new-generation hormonal therapy in patients with prostate cancer: A systematic review 29
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial 28
Therapeutic sequencing in advanced renal cell carcinoma: how to choose considering clinical and biological factors 27
Darolutamide in Metastatic Prostate Cancer 25
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy 25
The prognostic value of pain in castration-sensitive prostate cancer 25
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond 23
Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? 23
How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy? 17
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis 7
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma 6
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer 6
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis 4
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis 2
Totale 8.650
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.288
article - articoli 0
book - libri 0
conference - conferenze 249
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.537
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019340 0 0 0 0 0 0 0 0 0 0 213 127
2019/20201.399 108 95 61 150 92 140 148 119 180 110 94 102
2020/20211.235 56 107 92 112 145 102 121 82 93 82 100 143
2021/20221.128 95 79 77 92 73 60 80 53 70 85 254 110
2022/20231.491 120 170 57 120 152 290 93 122 160 55 97 55
2023/2024816 89 139 57 77 70 136 69 73 21 73 12 0
Totale 8.650